Author  
Place of duty  
Title   인체 신세포암과 방광암 세포주에 대한 림프킨 활성 살해 세포와 Interleukin - 2 활성 종양침윤 림프구의 항암효과에 대한 연구 ( Antitumor Activity of Lymphokine Activated Killer Cells ( LAK ) and Interleukin-2 Activated Tumor Infiltrating Lymphocytes ( TIL ) to the Cell Lines of Human Renal cell carcinom
Publicationinfo   1990 Jan; 022(02): 286-298.
Key_word  
Full-Text  
Abstract   We analysed the antitumor activity of lymphokine activated killer cells (LAK) induced from peripheral bloods of normal, renai cells carcinoma and transitional cell carcinoma patients and interleukin-2 (IL-2) activated tumor infiltrating lymphocytes (TIL) from human renal cell carcinoma and transitional cell carcinoma of the bladder. An establidhed human renal cell carcinoma (Caki-1l and transitiunai cell carcinoma cell lines (T-24) were used as target cell. Cytotoxicity was checked by MTT assay. As a pilot study, concentration of IL-2 produced by KAIST was measured using IL-2 dependent CTLL cell compared with Cetus standard unit and optimun conditions for LAK generation were evaiuated. The concentration of IL-2 was 2 x 10(6) Cetus units/mg. The optimum target cell number was 5 x 10(3) cells in Caki-1 and 2.5 x 10(3) cells in T-24 cell line. Most active LAK cells were induced by 1,000 units,' m1 of IL-2 concentration and 5 days incubation period. The LAK activity of 10 normal adults (group 1), 10 renal celi carcinoma (group 2) and 9 transitional cell carcinoma patients lgroup 3) ta the target cells were compared. More than 50% of target cells were killed when effector; target cell ratio was 10 or more. The killing activities against the T-24 and Caki-1 cell lines were not different in all three groups. The tunwr infiltrating lymphocytes from 10 renal cell and 9 transitional cell carcinomas were activated with 1,000 units/ml of IL-2. TIL was activated in 7 of 19 tumor tissues. TIL from renal cell carcinoma showed good proliferating potential and nonspecific killing activity to the T-24 and Caki-l. The killing activity of TIL appeared to be somewhat stronger than LAK. Adoptive immunotherapy using LAK and TIL cauid provide a good therapeutic modality in the patients with advanced renai cell carcinoma and transitional cell carcinoma of the bladder.
저 자   이종욱(Chong Wook Lee),이은식(Eun Sik Lee),허대석(Dae Seog Heo),박재갑(Jae Gahb Park)